CGEM — Cullinan Oncology Cashflow Statement
0.000.00%
Last trade - 00:00- $717.90m
- $251.03m
- 30
- 28
- 94
- 49
Annual cashflow statement for Cullinan Oncology, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -21.7 | -59.5 | -67.5 | 109 | -155 |
| Depreciation | |||||
| Non-Cash Items | 0.552 | 22.8 | 27.5 | -247 | 20.9 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.135 | 6.85 | -3.54 | 11.2 | -0.339 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -20.9 | -29.8 | -43.4 | -127 | -134 |
| Capital Expenditures | -0.02 | -0.01 | 0 | -1.13 | -0.208 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -35.4 | -5.41 | -334 | 250 | 36 |
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -35.4 | -5.42 | -334 | 249 | 35.8 |
| Financing Cash Flow Items | 1.47 | 0.993 | -1.76 | -32.1 | 0 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 85.7 | 140 | 269 | -25.9 | 40.8 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 29.4 | 105 | -108 | 96.4 | -57.7 |